DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Tyrosine kinase
Tyrosine kinase
Tyrosine Kinase – Role and Significance in Cancer
Ephb3 Suppresses Non-Small-Cell Lung Cancer Metastasis Via a PP2A/RACK1/Akt Signalling Complex
Erbb3 Is Involved in Activation of Phosphatidylinositol 3-Kinase by Epidermal Growth Factor STEPHEN P
Human Ephb3 Antibody Antigen Affinity-Purified Polyclonal Sheep Igg Catalog Number: AF5667
PDGFRB FISH for Gleevec Eligibility in Myelodysplastic Syndrome/Myeloproliferative Disease (MDS/MPD)
Targeting the Function of the HER2 Oncogene in Human Cancer Therapeutics
Expression of the Tyrosine Kinase Receptor Epha5 and Its Ligand Ephrin- AS During Mouse Spinal Cord Development
Genetic Testing for Germline Mutations of the RET Proto-Oncogene AHS - M2078
Review Diverse Roles of Eph Receptors and Ephrins in The
EGFR and HER2 Small Molecules Inhibitors As Potential Therapeutics in Veterinary Oncology
KIT Somatic Mutations and Immunohistochemical Expression in Canine Oral Melanoma
The Erbb/HER Family of Protein-Tyrosine Kinases and Cancer
Activating Mutations in HER2: Neu Opportunities and Neu Challenges
Eph Receptor Signalling: from Catalytic to Non-Catalytic Functions
The Erbb/HER Receptor Protein-Tyrosine Kinases and Cancerq
A Selective Small Molecule C-MET Inhibitor, PHA665752, Cooperates with Rapamycin
Tyrosine Kinase Inhibitors in Cancer: Breakthrough and Challenges of Targeted Therapy
HER2/Neu: an Increasingly Important Therapeutic Target
Top View
Novel Roles of Erbb3 Receptor Tyrosine Kinase in Vesicular Trafficking
Small Molecule Tyrosine Kinase Inhibitors of Erbb2/HER2/Neu in the Treatment of Aggressive Breast Cancer
Receptor Tyrosine Kinase Signalling As a Target for Cancer Intervention Strategies
Harnessing the Power of Eph/Ephrin Biosemiotics for Theranostic Applications
Trastuzumab Is Not a Tyrosine Kinase Inhibitor Nishant Mohan and Wen Jin Wu
Pdgfrβ Kinase Assay by Jolanta Vidugiriene, Ph.D., Hicham Zegzouti, Ph.D., and Said A
THE ROLE of the Ret PROTO-ONCOGENE in HUMAN DISEASE
C-Met and Other Cell Surface Molecules: Interaction, Activation and Functional Consequences
Clinical Use of Tyrosine Kinase Inhibitors: Therapy for Chronic Myelogenous Leukemia and Other Cancers
A Tyrosine Kinase-Activating Variant Asn666ser in PDGFRB Causes a Progeria-Like Condition in the Severe End of Penttinen Syndrome
Mechanisms of Receptor Tyrosine Kinase Activation in Cancer Zhenfang Du1 and Christine M
Exploiting Insights on the RET Receptor for Personalized Cancer Medicine
Structure and Regulation of Kit Protein-Tyrosine Kinase—The Stem Cell Factor Receptor Q
De-Repression of Pdgfrb Transcription Promotes Acquired
TNF Down-Regulation of Receptor Tyrosine Kinase
Novel Therapeutic Inhibitors of the C-Met Signaling Pathway in Cancer Joseph Paul Eder,1George F
Oncogenic Mutation in the Kit Receptor Tyrosine Kinase Alters Substrate
Erbb3/HER3 Intracellular Domain Is Competent to Bind ATP and Catalyze Autophosphorylation